|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPSM2 |
Gene summary for GPSM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPSM2 | Gene ID | 29899 |
| Gene name | G protein signaling modulator 2 | |
| Gene Alias | CMCS | |
| Cytomap | 1p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000132 | UniProtAcc | A0A024R0F8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29899 | GPSM2 | CA_HPV_3 | Human | Cervix | CC | 1.23e-05 | 2.70e-01 | 0.0414 |
| 29899 | GPSM2 | CCI_1 | Human | Cervix | CC | 3.07e-02 | 4.69e-01 | 0.528 |
| 29899 | GPSM2 | CCI_2 | Human | Cervix | CC | 2.41e-03 | 6.30e-01 | 0.5249 |
| 29899 | GPSM2 | CCI_3 | Human | Cervix | CC | 3.70e-02 | 5.02e-01 | 0.516 |
| 29899 | GPSM2 | LZE22T | Human | Esophagus | ESCC | 2.93e-03 | 3.12e-01 | 0.068 |
| 29899 | GPSM2 | P2T-E | Human | Esophagus | ESCC | 7.79e-04 | 2.63e-01 | 0.1177 |
| 29899 | GPSM2 | P4T-E | Human | Esophagus | ESCC | 1.53e-09 | 2.46e-01 | 0.1323 |
| 29899 | GPSM2 | P5T-E | Human | Esophagus | ESCC | 1.33e-11 | 2.47e-01 | 0.1327 |
| 29899 | GPSM2 | P8T-E | Human | Esophagus | ESCC | 1.71e-02 | 1.11e-02 | 0.0889 |
| 29899 | GPSM2 | P9T-E | Human | Esophagus | ESCC | 1.14e-02 | 1.49e-01 | 0.1131 |
| 29899 | GPSM2 | P10T-E | Human | Esophagus | ESCC | 3.49e-05 | 2.99e-01 | 0.116 |
| 29899 | GPSM2 | P11T-E | Human | Esophagus | ESCC | 5.91e-09 | 2.34e-01 | 0.1426 |
| 29899 | GPSM2 | P12T-E | Human | Esophagus | ESCC | 2.86e-03 | 1.88e-01 | 0.1122 |
| 29899 | GPSM2 | P15T-E | Human | Esophagus | ESCC | 2.78e-02 | 1.50e-01 | 0.1149 |
| 29899 | GPSM2 | P17T-E | Human | Esophagus | ESCC | 4.31e-03 | 5.52e-01 | 0.1278 |
| 29899 | GPSM2 | P19T-E | Human | Esophagus | ESCC | 3.01e-04 | 5.69e-01 | 0.1662 |
| 29899 | GPSM2 | P20T-E | Human | Esophagus | ESCC | 6.85e-22 | 6.69e-01 | 0.1124 |
| 29899 | GPSM2 | P21T-E | Human | Esophagus | ESCC | 1.72e-11 | 3.01e-01 | 0.1617 |
| 29899 | GPSM2 | P23T-E | Human | Esophagus | ESCC | 1.28e-10 | 6.15e-01 | 0.108 |
| 29899 | GPSM2 | P24T-E | Human | Esophagus | ESCC | 3.54e-06 | 2.85e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
| GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
| GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
| GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
| GO:19043779 | Cervix | CC | positive regulation of protein localization to cell periphery | 24/2311 | 69/18723 | 1.21e-06 | 4.15e-05 | 24 |
| GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
| GO:005149510 | Cervix | CC | positive regulation of cytoskeleton organization | 50/2311 | 226/18723 | 2.53e-05 | 4.29e-04 | 50 |
| GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
| GO:00900685 | Cervix | CC | positive regulation of cell cycle process | 50/2311 | 236/18723 | 8.25e-05 | 1.11e-03 | 50 |
| GO:19043758 | Cervix | CC | regulation of protein localization to cell periphery | 30/2311 | 125/18723 | 2.28e-04 | 2.56e-03 | 30 |
| GO:19021153 | Cervix | CC | regulation of organelle assembly | 40/2311 | 186/18723 | 2.92e-04 | 3.15e-03 | 40 |
| GO:19021171 | Cervix | CC | positive regulation of organelle assembly | 19/2311 | 67/18723 | 3.42e-04 | 3.58e-03 | 19 |
| GO:00705074 | Cervix | CC | regulation of microtubule cytoskeleton organization | 32/2311 | 148/18723 | 1.02e-03 | 8.51e-03 | 32 |
| GO:00618425 | Cervix | CC | microtubule organizing center localization | 11/2311 | 33/18723 | 1.42e-03 | 1.11e-02 | 11 |
| GO:00516425 | Cervix | CC | centrosome localization | 10/2311 | 32/18723 | 3.96e-03 | 2.48e-02 | 10 |
| GO:00516572 | Cervix | CC | maintenance of organelle location | 5/2311 | 11/18723 | 6.92e-03 | 3.74e-02 | 5 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPSM2 | SNV | Missense_Mutation | c.1114C>G | p.Gln372Glu | p.Q372E | P81274 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GPSM2 | SNV | Missense_Mutation | c.1463G>C | p.Gly488Ala | p.G488A | P81274 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| GPSM2 | SNV | Missense_Mutation | c.1629C>A | p.Asn543Lys | p.N543K | P81274 | protein_coding | tolerated(0.49) | benign(0.015) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPSM2 | SNV | Missense_Mutation | rs867670266 | c.815N>T | p.Ala272Val | p.A272V | P81274 | protein_coding | tolerated(0.06) | probably_damaging(0.948) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GPSM2 | SNV | Missense_Mutation | c.1672N>A | p.Arg558Ser | p.R558S | P81274 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GPSM2 | SNV | Missense_Mutation | c.1258N>A | p.Glu420Lys | p.E420K | P81274 | protein_coding | tolerated(0.1) | benign(0.08) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GPSM2 | SNV | Missense_Mutation | c.970N>A | p.Ala324Thr | p.A324T | P81274 | protein_coding | deleterious(0.02) | benign(0.241) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
| GPSM2 | SNV | Missense_Mutation | c.1778C>A | p.Ala593Asp | p.A593D | P81274 | protein_coding | deleterious(0.03) | benign(0.078) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| GPSM2 | SNV | Missense_Mutation | novel | c.1525T>C | p.Cys509Arg | p.C509R | P81274 | protein_coding | deleterious(0) | possibly_damaging(0.677) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GPSM2 | SNV | Missense_Mutation | novel | c.1673G>C | p.Arg558Pro | p.R558P | P81274 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |